Skip to main content
Home

Search


NEI on Social Media | Search A-Z | en español | Text size S M L
  • About NEI
    • NEI Research Accomplishments
    • Budget and Congress
    • About the NEI Director
    • History of the NEI
    • NEI 50th Anniversary
    • NEI Women Scientists Advisory Committee (WSAC)
    • Board of Scientific Counselors
    • National Advisory Eye Council (NAEC)
    • Donating to the NEI

    Menu About NEI Block

     Contact Us

     Visiting the NIH Campus

    Mission Statement

    As part of the federal government’s National Institutes of Health (NIH), the National Eye Institute’s mission is to “conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.”

  • News & Events
    • Events Calendar
    • NEI Press Releases
    • News from NEI Grantees
    • Spokesperson bios
    • Statistics and Data
    • Resources for the media

    Pressroom Contacts

    Dustin Hays - Chief, Science Communication
    dustin.hays@nih.gov

    Kathryn DeMott, Media Relations
    Kathryn.DeMott@nih.gov

    NEI Office of Communications
    (301)496-5248

  • Health Information
    • Frequently asked questions
    • Clinical Studies
    • Spanish Language Information
    • Publications Catalog
    • Photos and Images
  • Grants and Funding
    • Extramural Research
    • Division of Extramural Science Programs
    • Division of Extramural Activities

    Extramural Contacts

    National Eye Institute
    Division of Extramural Research
    6700B Rockledge Dr., MSC 6914
    Bethesda, MD 20892
    (FedEx, UPS, and other courier services use: Bethesda MD 20817)
    301-451-2020

  • Research at NEI
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Laboratories, Sections and Units
    • eyeGENE
    • Division of Epidemiology and Clinical Applications

    Office of the Scientific Director

    Sheldon S. Miller, Ph.D., Scientific Director
    David M. Schneeweis, Ph.D., Deputy Scientific Director

    Office of the Clinical Director

    Brian P. Brooks, M.D, Ph.D., Clinical Director
    Emily Y. Chew, M.D., Deputy Clinical Director

  • Education Programs
    • National Eye Health Education Program (NEHEP)
    • Diabetic Eye Disease Education Program
    • Glaucoma Education Program
    • Low Vision Education Program
    • Hispanic/Latino Program
    • Vision and Aging Program
    • African American Program
  • Training and Jobs
    • Jobs
    • NEI Summer Intern Program
    • Diversity In Vision Research & Ophthalmology (DIVRO)
    • Student Training Programs

    To search for current job openings visit HHS USAJobs

Home » News » Pressreleases » Laser Treatment for Vision Loss from Branch Retinal Vein Occlusion is Safer than Corticosteroid Injections and Equally Effective
Listen

Topics

Age-Related Macular Degeneration (AMD)
AIDS-related eye disease (cytomegalovirus [CMV] retinitis)
Amblyopia
Anophthalmia and Microphthalmia
Appointments
Astigmatism
Audacious Goals Challenge
Awards
Behçet’s Disease of the Eye
Bietti's Crystalline Dystrophy
Blepharitis
Blepharospasm
Cataracts
Clinical Studies
coloboma
Color Blindness
Convergence Insufficiency (CI)
Cornea
Diabetic Eye Disease
Dry Eye
Education Programs
Eye Cancer
Eye Surgery
Floaters
Gene
Glaucoma
Healthy Vision Month
Hispanic/Latino Americans
Histoplasmosis
Hyperopia
Idiopathic Intracranial Hypertension
Infancy
Infectious Eye Disease
Leber Congenital Amaurosis (LCA)
Low Vision
Macular Degeneration
Macular Edema
Macular Hole
Macular Pucker
Myopia
NEI
NEI Remembers
NEI Website
Optic Nerve Disorders
Pink Eye (Conjunctivitis)
Preschool
Rare Diseases
Refractive Errors
Refractive Surgery
Retina
Retinal Disease
Retinitis Pigmentosa
Retinoblastoma
Retinopathy of Prematurity (ROP)
Retinoschisis
Spanish
Spanish
Stargardt Disease
Stem Cells
Usher Syndrome
Uveitis/Inflammatory Eye Disease
Vision Screening
World Sight Day

Laser Treatment for Vision Loss from Branch Retinal Vein Occlusion is Safer than Corticosteroid Injections and Equally Effective

Press Release
09/14/09

Scientists have found that laser therapy is equivalent to two different dosages of corticosteroid medications for treating vision loss from the blockage of small veins in the back of the eye, a condition known as branch retinal vein occlusion (BRVO). Furthermore, laser treatment was shown to have fewer complications for patients.

This research was part of the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study, a phase III clinical trial conducted at 84 sites and supported by the National Eye Institute (NEI) at the National Institutes of Health.

“The SCORE study is the first to demonstrate that laser treatment and injections of corticosteroid into the eye have a similar impact on vision loss for patients who have retinal swelling due to branch retinal vein occlusion,” said Ingrid U. Scott, M.D., M.P.H., professor at Penn State College of Medicine and co-chair of the SCORE study. “However, the lower rate of complications with laser treatment may indicate that it is the best proven treatment option for patients at this time, and that laser represents the benchmark against which other treatments should be compared in future clinical trials.”

In the United States, vein occlusion is estimated to be the second most common condition affecting blood vessels in the retina. In BRVO, a blood clot slows or stops circulation in a small vein within the eye’s light-sensitive retinal tissue. This may lead to new blood vessel growth and blood vessel leakage, which results in retinal tissue swelling—a common cause of vision loss from BRVO.

Eye doctors typically treat BRVO with laser therapy applied to the affected retina in a grid pattern. However, some ophthalmologists have treated people who have BRVO using eye injections of an anti-inflammatory corticosteroid called triamcinolone. Because clinical observations suggested a visual benefit, the SCORE study was initiated to compare the safety and effectiveness of standard care laser treatment with two different doses of triamcinolone—1 milligram and 4 milligrams. The results appear in the September 2009 issue of Archives of Ophthalmology, published alongside findings from a separate trial within the SCORE study, which looked at blockages in larger retinal veins (http://www.nei.nih.gov/news/pressreleases/091409a).

Participants in the study included 411 people with BRVO who were an average of 67 years old. Patients could receive treatment every four months for up to three years. One year after patients began the trial, equal numbers of patients experienced visual improvement in each treatment group. Twenty to 30 percent of patients in each group experienced substantial visual gains of three or more lines on a vision chart—equivalent to identifying letters that were half as small as they could read before treatment.

However, patients who received either dosage of corticosteroid medication were more likely to develop a cataract or have an increase in eye pressure requiring medication than patients who received laser treatment. Between one and two years after treatment was begun, patients who received the 4 milligram dosage were also more likely to undergo cataract surgery.

“These results may have a significant public health impact by providing guidance for clinicians and patients in their selection of a branch retinal vein occlusion treatment,” said Frederick L. Ferris III, M.D., clinical director of the NEI. “Still, better treatments for this condition are needed. This information could guide future clinical trials of new and more effective treatments for BRVO patients.”

The SCORE study was co-chaired by Michael S. Ip, M.D., associate professor at the University of Wisconsin, Madison, and Ingrid U. Scott, M.D., M.P.H., professor at Penn State College of Medicine. Find more information about this clinical trial (NCT00105027) at www.clinicaltrials.gov.

# # #

The National Eye Institute (NEI), part of the National Institutes of Health, leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit www.nei.nih.gov.

The National Institutes of Health (NIH) - The Nation’s Medical Research Agency - includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

  • NEI Home
  • Contact Us
  • A-Z Site Map
  • NEI on Social Media
  • Information in Spanish (Información en español)
  • Website, Social Media Policies and Other Important Links
  • NEI Employee Emergency Information
  • NEI Intranet (Employees Only)
  • Department of Health and Human Services
  • The National Institutes of Health
  • USA.gov

*PDF files require the free Adobe® Reader® software for viewing.

Technical questions about this website can be addressed to the NEI Website Manager.